Carrick means ‘rock’ in Irish, the name having been chosen to emphasise the strong foundation of like-minded scientists, collaborators and investors, and the vision to build a durable world-class company. Carrick has an ambitious patient focussed vision to serve cancer patients around the world by the introduction of ground-breaking cancer therapies that will transform the way cancer is treated.
Carrick has a clear vision for cancer patients: to target the molecular pathways that drive the most aggressive and resistant forms of cancer in order to have a major impact on the lives of patients. Carrick is building an innovative portfolio of first-in-class treatments that are advanced through understanding the mechanisms that cause cancer and resistance and are tailored to an individual patient’s tumour.
One of Carrick’s founding scientific programmes is derived from work undertaken at the Gurdon Institute in Cambridge. This was licensed by Cambridge Enterprise, the commercialisation arm of the University of Cambridge.
In 2016 Carrick received $95 million of funding from ARCH Venture Partners, Woodford Investment Management, Cambridge Enterprise, Evotec AG, GV (Google Ventures) and Lightstone Ventures, alongside CIC.
The company announced in November 2017 that the first patient had been dosed in the phase 1 clinical programme of CT7001 – an orally bio-available Cyclin-dependent Kinase 7 (CDK7) selective inhibitor, that has shown striking efficacy in multiple pre-clinical cancer models.
CIC point of contact: Robert Tansley